Overview
IMUX market data
Price History
IMUX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$6.24 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.43 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.06 – $16.86 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $225.3M · P/B 4.89.
Company News
8-K filing — IMMUNIC, INC. (IMUX)SEC EDGAR · Aug 11, 2026, 11:05 AM
Immunic Q2 EPS $(0.80) Beats $(1.10) EstimateBenzinga · Aug 11, 2026, 10:36 AM
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEOBenzinga · May 27, 2026, 10:17 AM
EXCLUSIVE: Immunic Appoints Former Genentech Executive Erik Lundgren As CEO To Fire Up MS Drug Launch; He Joins Effective May 22, Employment Begins June 1Benzinga · May 27, 2026, 10:16 AM
B. Riley Securities Maintains Buy on Immunic, Lowers Price Target to $27Benzinga · May 22, 2026, 2:20 PM